|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01873 VIVA BIOTECH
Nominal 
0.910 -0.020 (-2.151%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 2,155,578 | -9.415% | 2,379,631 | 2,104,083 | 696,958 | 323,057 |
| Cost of Sales | (1,417,146) | -9.387% | (1,563,952) | (1,453,102) | (392,092) | (167,184) |
| Gross Profit | 738,432 | -9.470% | 815,679 | 650,981 | 304,866 | 155,873 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 154,515 | -- | (363,539) | 181,738 | (443,136) | 181,580 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | (17,909) | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | (487) | (1,908) | |
| Profit / (Loss) before Taxation | (55,953) | -87.814% | (459,165) | 347,701 | (356,210) | 280,925 | |
| Taxation | (43,837) | -2.703% | (45,055) | (47,141) | (22,660) | (15,053) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (16,323) | -32.703% | (24,255) | (13,014) | (8,010) | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (116,113) | -78.029% | (528,475) | 287,546 | (386,880) | 265,872 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 149,207 | -8.500% | 163,068 | 156,533 | 45,424 | (12,825) |
| Depreciation & Amortisation | 208,389 | 16.875% | 178,301 | 150,851 | 68,660 | 33,638 |
| Directors' Emoluments | 9,655 | -7.342% | 10,420 | 9,187 | 6,534 | 7,995 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified (Modified Report) | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -6.000 | -78.571% | -28.000 | 15.000 | -25.000 | 19.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 2.277 | 1.818 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | 9.570% |
| Cash flow per share ($) | 0.198 | -- | 0.202 | 0.041 | 0.027 | 0.033 |
| NBV per share ($) | 1.706 | -- | 1.643 | 1.780 | 1.714 | 1.138 |
| Remarks: | Real time quote last updated: 11/11/2024 10:01 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 116,808,000 |
| %Change | 11430.898% |
| EPS / (LPS) | RMB 0.050 |
| NBV Per Share (¥) | RMB 1.753 |